Please login to the form below

Not currently logged in
Email:
Password:

Pfizer brings cancer pipeline to forefront

Pfizer has revealed that a number of its pipeline cancer compounds have advanced to phase III clinical development

Pfizer has revealed that a number of its pipeline cancer compounds have advanced to phase III clinical development.

The world's largest pharmaceutical firm presented data at a meeting with financial analysts on 4 June at the American Society of Clinical Oncology annual meeting (ASCO) in Chicago, Illinois.

The company highlighted the following oncology compounds that are currently in phase III trials as well as additional compounds expected to advance into phase III trials in 2008:

1) Sutent: phase III for breast cancer/ new phase III for non-small-cell lung, colorectal, and liver cancer
2) Axitinib: phase III for thyroid cancer/ new phase III for pancreatic cancer
3) CP-751,871: phase III for melanoma/ new phase III data available 2008
4) PF 3,512,676: for non-small-cell lung cancer/ new phase III data available 2008

Pfizer currently invests more than 20 per cent of its development budget in oncology research, with active programmes in immunotherapy, signal transduction inhibition and angiogenesis inhibition.

During the past five years, the number of R&D oncology projects in Pfizer has increased dramatically. There are 30 programmes in preclinical development, while 16 oncology compounds are in phase I-III clinical development, which include four compounds

in phase II and three compounds, as well as a potential additional indication for Sutent (sunitinib), currently in phase III.

At the conference, Pfizer and other pharmaceutical companies presented pipeline cancer treatments, which it hopes will boost profits after a number of high-profile late-stage clinical failures.

Pfizer has experienced increasing generic erosion of its mainstay drugs, with its top-selling cholesterol-lowering drug, Lipitor (atorvastatin) an example. The market for cancer drugs is expected to rise to USD 70bn in 2009 from USD 42bn in 2004, according to GlaxoSmithKline (GSK).

Bear Stearns analysts have estimated that oncology products make up around 40 per cent of Pfizer's pipeline and could generate about USD 2.1bn.

7th June 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics